- New State-of-the-Art Building To Be Located in
Scientific Research Park, Granta Park, and Will Serve As Illumina's
New European Headquarters
SAN DIEGO, June 25, 2015 /PRNewswire/ -- BioMed Realty
Trust, Inc. (NYSE: BMR) today announced that Illumina, Inc.
(NASDAQ: ILMN), a world leader in genomics focused on improving
human health by unlocking the power of the genome, has signed a
20-year lease for a 155,000 square foot new and innovative
scientific research building in Cambridge, England. The project will provide
Illumina a collaborative environment and access to the highly
skilled workforce in the dynamic research cluster anchored by
Cambridge University.
The project advances state-of-the-art design, with plans to be
able to seamlessly expand by 70,000 square feet into a 225,000
square foot building. BioMed Realty acquired the land for the
project from The Welding Institute under a long term ground lease,
enlarging BioMed Realty's Granta Park campus in Cambridge, England.
"Illumina and BioMed Realty's commitment to building a new
state-of-the art facility in Cambridge is great news for our area," said
George Freeman, Parliamentary Under
Secretary of State for Life Sciences at the UK Department for
Business, Innovation and Skills and the Department of Health. "This
is a strong endorsement of the UK's Life Science Industrial
Strategy and leadership in driving forward better treatments for
people with cancers and rare diseases."
"Illumina is proud of its heritage and presence in the
Cambridge area, and welcomes the
opportunity to continue our strong investment in the UK," said
Marc Stapley, Chief Financial
Officer for Illumina. "This new state-of-the-art European
Headquarters will provide enhanced collaboration opportunities for
our growing employee base, which is so foundational to Illumina's
innovation and success."
BioMed Realty owns, manages and operates Granta Park, a
scientific research center, located eight miles from Cambridge University and currently comprising
472,200 square feet of laboratory and office space. Last year, the
company acquired a 42,400 square foot build-to-suit property in
development for Takeda Pharmaceutical Company in the Cambridge
Science Park. With today's announcement of Illumina's new building,
BioMed Realty's presence in the Cambridge, England market is approaching
700,000 square feet.
"BioMed Realty is delighted to announce that Illumina has
selected Granta Park as its European headquarters and to be
expanding our relationship with Illumina into Europe," said Alan
Gold, Chairman, President and CEO of BioMed Realty.
"Cambridge shares key common
characteristics with our core U.S. markets which is why we decided
to enter the market and why we continue to grow there."
About BioMed Realty Trust
BioMed Realty, with its trusted expertise and valuable
relationships, delivers optimal real estate solutions for
biotechnology and pharmaceutical companies, scientific research
institutions, government agencies and other entities involved in
the life science industry. BioMed Realty owns or has interests in
properties comprising approximately 18.3 million rentable square
feet. Additional information is available at
www.biomedrealty.com. Follow us on Twitter @biomedrealty.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
based on current expectations, forecasts and assumptions that
involve risks and uncertainties that could cause actual outcomes
and results to differ materially. These risks and uncertainties
include, without limitation: risks and uncertainties affecting
property development and construction, including the development of
the building for Illumina in Cambridge,
UK; failure to manage effectively the company's growth and
expansion into new markets, or to complete or integrate
acquisitions and developments successfully; and general risks
affecting the real estate industry (including, without limitation,
the inability to enter into or renew leases, dependence on tenants'
financial condition, and competition from other developers, owners
and operators of real estate). For a further list and description
of such risks and uncertainties, see the reports filed by the
company with the Securities and Exchange Commission, including the
company's most recent annual report on Form 10-K and quarterly
reports on Form 10-Q. The company disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.